Rapid Increase of Resistance to Erythromycin and Clindamycin in Streptococcus pyogenes in Italy, 1993-1995

Emerging Infectious Diseases

Volumn 2, Issue 4, 1996, Pages 339-342

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CLINDAMYCIN; DNA BINDING PROTEIN; ERYTHROMYCIN; ETV5 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; ITALY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLINDAMYCIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, MICROBIAL; ERYTHROMYCIN; HUMANS; ITALY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TRANSCRIPTION FACTORS;

EID: 0030256910     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0204.960410     Document Type: Article

References (26)

1. Stevens DL. Streptococcal toxic shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerging Infectious Diseases 1995;1:69-78.
2. Kaplan EL. The resurgence of group A streptococcal infections and their sequelae. Eur J Clin Microbiol Infect Dis 1991;10:55-7.
3. Musher DM, Hamill RJ, Wright CE, Clarridge JE, Ashton CM. Trends in bacteremic infection due to Streptococcus pyogenes (group A streptococcus), 1986-1995. Emerging Infectious Diseases 1996;2:54-6.
4. Strömberg A, Romanus V, Burman LG. Outbreak of Group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J Infect Dis 1991;164:595-8.
5. Martin PR, Höiby EA. Streptococcal serogroup A epidemic in Norway 1977-1988. Scand J Infect Dis 1990;22:421-9.
6. Duval J. Evolution and epidemiology of MLS resistance. J Antimicrob Chemother 1985;16:137-49.
7. Stingemore N, Francis GR, Toohey M, McGeechie DB. The emergence of erythromycin resistance in Streptococcus pyogenes in Fremantle, Western Australia. Med J Aust 1989;150:626-31.
8. Seppälä H, Nissinen A, Järvinen H, Huovinen S, Henriksson T, Herva E, et al. Resistance to erythromycin in Group A streptococci. N Engl J Med 1992;326:292-7.
9. Phillips G, Parratt D, Orange GV, Harper I, McEwan H, Young N. Erythromycin-resistant Streptococcus pyogenes. J Antimicrob Chemother 1990;25:723-4.
10. Maruyama SH, Yoshioka H, Fujiita K, Takimoto M, Satake Y. Sensitivity of group A streptococci to antibiotics: prevalence of resistance to erythromycin in Japan. Am J Dis Child 1979;133:1143-5.
11. Hsueh P-R, Chen H-M, Huang A-Y, Wu J-J. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother 1995;39:2239-42.
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: sixth informational supplement. National Committee for Clinical Laboratory Standards document M100-S6. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1995.
13. Borzani M, Varotto F, Garlaschi L, Conio F, Dell'Olio M, Careddu P. Clinical and microbiological evaluation of miocamycin activity against group A in pediatric patients: three years' incidence of erythromycin resistant group A streptococci. J Chemother 1989;1:35-8.
14. Scopetti F, Pataracchia M, Pacifico L, Ranucci A, Morini C, Cherchi G, et al. A multicenter study on antimicrobial susceptibility and typing of group A streptococci from cases of pharyngo-tonsillitis and scarlet fever. Microecology and Therapy 1995;25:348-55.
15. Cellesi C, Chigiotti S, Zanchi A, Mencarelli M, Corbisiero R, Rossolini GM. Susceptibility to macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. J Chemother 1996;8:188-92.
16. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1993.
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, M2-A5. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1993.
18. Cornaglia G, Satta G. MyMic: computerised listing of antimicrobials with optimal activity and pharmacokinetic properties for individual infections. Binary 1993;5:159-64.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: fifth informational supplement. National Committee for Clinical Laboratory Standards document M100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1994.
20. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Ghemother 1995;39:577-85.
21. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae, and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux systems. Antimicrob Agents Chemother 1996;40:1817-24.
22. Arthur M, Molinas C, Mabilat C, Courvalin P. Detection of erythromycin resistance by the polymerase chain reaction using primers in conserved regions of erm rRNA methylase genes. Antimicrob Agents Chemother 1990;34:2024-6.
23. Arthur M, Brisson-Noël A, Courvalin P. Origin and evolution of genes specifying resistance to macrolide, lincosamide and streptogramin antibiotics: data and hypothesis. J Antimicrob Chemother 1987;20:783-802.
24. Macrina FL, Jones KR, Wood PH. Chimeric plasmids and their use as molecular cloning vehicles in Streptococcus sanguis (Challis). J Bacteriol 1980;143:1425-35.
25. Seppälä H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993;32:885-91.
26. Leclerq R, Courvalin P. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991;35:1267-72.